Synlogic Provides Corporate Update and Outlook for 2024
– Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age –
– Top-line, Phase 3 data in PKU expected in H1 2025 –
Related news for (SYBX)
- Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
- Sidoti Events, LLC’s Virtual January Micro-Cap Conference
- Synlogic Announces Contract with the Air Force Research Lab
- Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023